Latest Earnings Analysis

• AppLovin (APP) Q2 2023: Axon 2.0 Powers 28% Software Platform Growth, Setting New Margin Baseline
  August 09, 2023 · APP
• AOSL Q4 2023: Computing Rebounds 36.8%, Inventory Correction Drives Sequential Recovery
  August 09, 2023 · AOSL
• ANI Pharmaceuticals (ANIP) Q2 2023: Rare Disease Revenue Surges 138%, Driving Up Full-Year Guidance
  August 09, 2023 · ANIP
• AMSC (AMSC) Q1 2023: Grid Revenue Jumps 30% as Backlog Diversifies, Margin Path Clears
  August 09, 2023 · AMSC
• BCSF Q2 2023: Dividend Raised 11% as First Lien Debt Exposure Hits 82%
  August 09, 2023 · BCSF
• BigBear.ai (BBAI) Q2 2023: SG&A Down 37% as Margin Mix Shifts Toward Tech-Led Contracts
  August 08, 2023 · BBAI
• Allbirds (BIRD) Q2 2023: Inventory Down 24%, Distributor Model Targets Immediate Profitability Shift
  August 08, 2023 · BIRD
• ASLE Q2 2023: Feedstock Acquisition Tops $200M as Cargo Weakness Drives Guidance Reset
  August 08, 2023 · ASLE
• Azenta (AZTA) Q3 2023: Automated Store Revenue Jumps 15%, Underscoring Workflow Automation Tailwind
  August 08, 2023 · AZTA
• AECOM (ACM) Q3 2023: Design Backlog Climbs 10%, Sharpening Multi-Year Growth Visibility
  August 08, 2023 · ACM
• Brookdale Senior Living (BKD) Q2 2023: 61% EBITDA Surge Highlights Fixed Cost Leverage and Occupancy Upside
  August 08, 2023 · BKD
• Backblaze (BLZE) Q2 2023: B2 Cloud Storage Climbs to 44% of Revenue, Fueling Upmarket Expansion
  August 08, 2023 · BLZE
• Bumble (BMBL) Q2 2023: Paying Users Jump 20% as Product Innovation Drives Engagement
  August 08, 2023 · BMBL
• Aramark (ARMK) Q3 2023: Global FSS Surges 16% as Margin Recovery Accelerates
  August 08, 2023 · ARMK
• Acumen Pharmaceuticals (ABOS) Q2 2023: $122M Capital Raise Extends Runway for Phase 2–3 Alzheimer’s Trial
  August 08, 2023 · ABOS
• Arcutis (ARQT) Q2 2023: 40% TRX Growth Signals Coverage Gains, Setting Up Multi-Indication Expansion
  August 08, 2023 · ARQT
• Array Technologies (ARRY) Q2 2023: Gross Margin Expands 2,010bps as Non-Tracker Revenue, Cost Discipline Drive Profitability
  August 08, 2023 · ARRY
• Atkore (ATKR) Q3 2023: $416M Buybacks, Volume Up 7% Ex-PVC Signal Durable Core Growth
  August 08, 2023 · ATKR
• AWR Q2 2023: Rate Base Set to Climb 10.5% Annually as Regulatory Clarity Unlocks Capital Deployment
  August 08, 2023 · AWR
• Abiona Therapeutics (ABEO) Q2 2023: $25M Raise Extends Runway Past Potential EB101 Launch
  August 08, 2023 · ABEO
• AFC Gamma (AFCG) Q2 2023: $43M Underperforming Debt Monetized as Portfolio Risk Repositioning Accelerates
  August 08, 2023 · AFCG
• Axon (AXON) Q2 2023: Cloud Revenue Jumps 62% as Premium Bundles Drive SaaS Expansion
  August 08, 2023 · AXON
• Akamai (AKAM) Q2 2023: Security and Compute Surge 30%, Now 54% of Revenue
  August 08, 2023 · AKAM
• AdaptHealth (AHCO) Q2 2023: Sleep and Respiratory Revenue Up 15%, Offsetting Diabetes Headwinds
  August 08, 2023 · AHCO
• Ascent Industries (ACNT) Q2 2023: Munhall Exit Drives $6.4M Non-Cash Charge, Resets Core Focus
  August 08, 2023 · ACNT
• Amphastar (AMPH) Q2 2023: Glucagon Sales Double, Drug Shortages Drive 47% Surge in Hospital Products
  August 08, 2023 · AMPH
• BARK (BARK) Q1 2024: Gross Margin Surges 280bps as Consumables Expansion Sets Up Retail Pivot
  August 08, 2023 · BARK
• ADC Therapeutics (ADCT) Q2 2023: 17% Workforce Reduction Enables Pipeline Focus as Zynlonta Expands
  August 08, 2023 · ADCT
• BlackLine (BL) Q2 2023: Strategic Product Sales Dip to 20%, Forcing Execution Reset
  August 08, 2023 · BL
• AMC (AMC) Q2 2023: Per Patron Profitability Up 36% Globally, Food & Beverage Drives Margin Expansion
  August 08, 2023 · AMC
• American Vanguard (AVD) Q2 2023: Green Solutions Grow 21% as Channel Destocking Drives 10% Sales Decline
  August 08, 2023 · AVD
• Anika (ANIK) Q2 2023: OA Pain Management Soars 22% as Pipeline Accelerates $3B Market Reach
  August 08, 2023 · ANIK
• ADT (ADT) Q2 2023: $1.6B Commercial Sale Unlocks 11x Multiple, Refocuses on Core Smart Home Growth
  August 08, 2023 · ADT
• Digital Turbine (APPS) Q1 2024: U.S. Revenue Per Device Surges Past $6, Signaling Platform Monetization Upside
  August 08, 2023 · APPS
• Angel Oak Mortgage REIT (AOMR) Q2 2023: Warehouse Debt Cut 63% as High-Coupon Loan Rotation Accelerates
  August 08, 2023 · AOMR
• ATEA Pharmaceuticals (AVIR) Q2 2023: Sunrise-3 Expands to 330 Sites, Targeting High-Risk COVID-19 Patients
  August 08, 2023 · AVIR
• BioLife Solutions (BLFS) Q2 2023: Freezer Divestiture Targets 52% Pro Forma Margin, Refocuses on Core Consumables
  August 08, 2023 · BLFS
• American Public Education (APEI) Q2 2023: Rasmussen Revenue Falls 19% as Cost Cuts and Enrollment Shifts Reshape Outlook
  August 08, 2023 · APEI
• Farmer Mac (AGM) Q2 2023: Renewable Energy Loan Book Surges 122%, Signaling Expansion Beyond Core Ag Lending
  August 07, 2023 · AGM
• Biodesix (BDSX) Q2 2023: Core Lung Diagnostics Revenue Surges 58% as Test Volumes Hit Record Highs
  August 07, 2023 · BDSX
• Alto Ingredients (ALTO) Q2 2023: Capacity Utilization Jumps to 81% as Diversification Strategy Accelerates
  August 07, 2023 · ALTO
• BioNTech (BNTX) Q2 2023: R&D Spend Cut by €400M as COVID Vaccine Volumes Fall
  August 07, 2023 · BNTX
• Axogen (AXGN) Q2 2023: Scheduled Procedures Surge 20%, Shifting Revenue Mix and Margin Dynamics
  August 07, 2023 · AXGN
• ARKO (ARKO) Q2 2023: Merchandise Margin Hits 31.9% as Core Category Shift Drives Profit Expansion
  August 07, 2023 · ARKO
• ADTRAN (ADTN) Q2 2023: Optical Networking Falls 3% as Inventory Correction Hits Near-Term Outlook
  August 07, 2023 · ADTN
• ACVA Q2 2023: Market Share Jumps 17% as Tech-Driven Attach Rates and Margins Expand
  August 07, 2023 · ACVA
• Aquestive Therapeutics (AQST) Q2 2023: License and Royalty Revenue Jumps 168% as Epinephrine Pipeline Advances
  August 07, 2023 · AQST
• Axsome Therapeutics (AXSM) Q2 2023: Field Force Expands 60%, Targeting 44,000 Prescribers for Avelity
  August 07, 2023 · AXSM
• ADEA (ADEA) Q2 2023: 9 New Deals Anchor 90%+ Renewal Rate, Fueling IP-Driven Growth
  August 07, 2023 · ADEA
• Arcturus Therapeutics (ARCT) Q2 2023: R&D Expenses Jump 38% as Platform Advances Toward First Approval
  August 07, 2023 · ARCT